Grossman - Figure 15
Neoadjuvant Chemotherapy Does not Provide Enough Benefit Overall survival – Platinum-based combinations
FIG. 15: So we have Level I evidence and a meta-analysis showing that neoadjuvant chemotherapy improves outcome. Nevertheless, there has been reluctance to use this potentially life-saving modality because of several arguments against it, one of which is that neoadjuvant chemotherapy does not provide enough benefit.
This Figure illustrates data from the ABC meta-analysis[5] showing that overall survival is improved with neoadjuvant chemotherapy. The curves separate early and maintain separation for 10 years. How does this result compare with other cancers that commonly use chemotherapy with definitive therapy?
References
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202−5 http://dx.doi.org/10.1016/j.eururo.2005.04.006
